Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Cp (NQ: TECH )

64.57 +1.67 (+2.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,189,371
Open 62.62
Bid (Size) 51.95 (3)
Ask (Size) 66.80 (1)
Prev. Close 62.90
Today's Range 62.38 - 64.63
52wk Range 51.79 - 89.91
Shares Outstanding 158,150,379
Dividend Yield 0.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Advancing with Stability: Bio-Techne Benefits Investors with Growing Earnings and Stable Payouts
By the close of today, November 24, 2023, Bio-Techne (NASDAQ:TECH) will issue a dividend payout of $0.08 per share, resulting in an annualized dividend yield of 0.56%. Only those investors who owned... 
Via Benzinga
Earnings Scheduled For October 31, 2023
Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of... 
Via Benzinga

Performance

YTD
-21.76%
-21.76%
1 Month
+22.22%
+22.22%
3 Month
-18.02%
-18.02%
6 Month
-22.20%
-22.20%
1 Year
-25.27%
-25.27%

More News

Read More
Earnings Preview: Bio-Techne
Via Benzinga
Bio-Techne's Ex-Dividend Date Is Thursday, Here's What You Need To Know
Via Benzinga
Nurturing Growth: Bio-Techne Supports Investors with Growing Earnings
Via Benzinga
This Favorable Sign Appears On Bio-Techne's Chart
Via Benzinga
3 AI Stock-Split Stocks to Buy Now
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Healthcare Stocks to Keep an Eye On
Via The Motley Fool
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
What 4 Analyst Ratings Have To Say About Bio-Techne
Via Benzinga
Bio-Techne: Q3 Earnings Insights
Via Benzinga
3 Healthcare Stocks That Should Be on Every Investor’s Radar This Fall
Via InvestorPlace
Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
3 Biotech Stocks to Buy Before the Breakout
Via InvestorPlace
Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout
Via Benzinga
Analyst Expectations for Bio-Techne's Future
Via Benzinga
Earnings Outlook For Bio-Techne
Via Benzinga
Bio-Techne's Acquisition of Lunaphore Expands Its Spatial Biology Offerings
Via Benzinga
Lunaphore to Get Acquired by Bio-Techne
From Lunaphore
Via Business Wire
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
Via Benzinga
This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
Via InvestorPlace
5 Cheapest Health Care Stocks You Should Think About
Via Benzinga
5 Health Care Stocks That Are Diving - And May Rally
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.